China’s drug development explosion forces a US biotech reckoningnews2025-01-21T15:30:24+00:00January 21st, 2025|Endpoints News|
Ascentage estimates $133M in proceeds as it plans dual listingnews2025-01-21T15:11:16+00:00January 21st, 2025|Endpoints News|
Another US biotech emerges with drug candidate from China-based Keymednews2025-01-20T11:48:36+00:00January 20th, 2025|Endpoints News|
The embryo editing debate is back, revived by Nature articlenews2025-01-12T17:21:58+00:00January 12th, 2025|Endpoints News|
Lawmakers ask administration to tighten China trial rulesnews2025-01-10T20:03:11+00:00January 10th, 2025|Endpoints News|
Four biotechs emerge with $800M and in-licensed assets on Fridaynews2025-01-10T15:04:37+00:00January 10th, 2025|Endpoints News|
Another biotech scoops up asset from China-based Keymed and nabs $180Mnews2025-01-10T12:19:00+00:00January 10th, 2025|Endpoints News|
Exclusive: Avenzo picks up another ADC, this time with multi-partnered DualityBionews2025-01-07T12:00:59+00:00January 7th, 2025|Endpoints News|
WuXi Biologics to sell Irish vaccine site to Merck for $500Mnews2025-01-06T16:58:02+00:00January 6th, 2025|Endpoints News|
WuXi AppTec sells cell and gene therapy business to investornews2024-12-26T16:25:08+00:00December 26th, 2024|Endpoints News|
